Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 14/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28439966 | 0.92 | STAT3 (0.44) | STAT3 | |
| SCHEMBL29447713 | 0.91 | STAT3 (0.43) | STAT3 | |
| SCHEMBL29447476 | 0.88 | STAT3 (0.43) | STAT3SGMS2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20418435 | 0.88 | STAT3 (0.43) | STAT3SGMS2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29447575 | 0.87 | STAT3 (0.42) | STAT3SGMS2ELANE | |
| SCHEMBL29447631 | 0.87 | STAT3 (0.41) | STAT3SGMS2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28434204 | 0.87 | STAT3 (0.41) | STAT3SGMS2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28439969 | 0.87 | STAT3 (0.42) | STAT3SGMS2ELANE | |
| SCHEMBL29447616 | 0.86 | STAT3 (0.42) | STAT3SGMS2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20418612 | 0.85 | STAT3 (0.49) | STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | STAT3 1/4885SGMS2 2977/4885MEN1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.